Skip to main content
. 2025 Aug 26;25:425. doi: 10.1186/s12871-025-03285-7

Table 3.

Cardiopulmonary support (CPS) run details and adverse event

Group Total study population
(n = 67)
CPB
(n = 18)
mini-CPB
(n = 15)
VV-ECMO
(n = 28)
VA-ECMO
(n = 6)
P value
Planned, n (%) 54(80.6) 11(61.1) 13(86.7) 25(89.3) 5(83.3) 0.02
Cannulation, n (%)
 Peripheral cannulation 60(89.6) 12(66.7) 14(93.3) 28(100.0) 6(100.0) 0.03
 Central cannulation 7(10.4) 6(33.3) 1(6.7) 0(0.0) 0(0.0) 0.02
 Pump duration (min) 95.4 ± 55.1 43 ± 18.2 64 ± 23.7 139 ± 45.6 127 ± 34.2  < 0.01
 Mean pump flow (ml/kg) 52 ± 15.6 38 ± 19.7 36 ± 21.3 66 ± 14.7 35 ± 14.8  < 0.01
 Sweep gas flow (L/min) 1.8 ± 0.3 1.9 ± 0.2 1.9 ± 0.2 3.4 ± 0.4 2.1 ± 0.2 0.16
 Heparin free, n (%) 30(44.8) 0(0.0) 0(0.0) 26(92.9) 4(66.7)  < 0.01
 Total heparin dose (UI) 10,255 ± 10,701 26,578 ± 6816 7213 ± 867 2725 ± 364 4033 ± 361  < 0.01
 SaO2-R (%) \ \ \ 88.4 ± 2.7 \  < 0.01
 PaO2-R (mmHg) 140.1 ± 68.8 187.4 ± 45.1 192.5 ± 33.2 67.5 ± 8.6 206.2 ± 31.2 0.00
 PaCO2-R (mmHg) 42.7 ± 6.5 42.8 ± 6.6 41.9 ± 6.42 43.3 ± 7 42.4 ± 5.3 0.48
 SO2 (pre-oxygenator) 78.3 ± 6.2 76.8 ± 9.5 74.4 ± 8.4 68.5 ± 5.4 75.0 ± 6.5 0.01
 Lac-max (mmol/L) 2.2 ± 0.8 2.3 ± 0.8 2.4 ± 0.7 2.2 ± 0.7 1.9 ± 0.5 0.57
 ACT-max (seconds) 321 ± 230 655 ± 196 250 ± 40 169 ± 18 209 ± 17 0.04
 Major cannulation site bleeding, n (%) 9(13.4) 3(16.7) 2(13.3) 3(10.7) 1(16.7) 0.63
 Limb ischemia, n (%) 1(1.5) 1(5.6) 0(0.0) 0(0.0) 0(0.0) 0.67
 Vessel injury, n (%) 2(3.0) 1(5.6) 1(6.7) 0(0.0) 0(0.0) 0.72

CPB cardiopulmonary bypass, m-CPB modified cardiopulmonary bypass, VV-ECMO veno-venous extracorporeal membrane oxygenation, VA-ECMO veno-arterial extracorporeal membrane oxygenation, OR operating room, SaO2-R oxygen saturation of the right radial artery, PaO2-R oxygen partial pressure of the right radial artery, SO2 oxygen saturation, Lac-max intraoperative maximum lactate value, ACT-max intraoperative maximum activated clotting time